Company Filing History:
1 out of 45 
1 out of 4 
1 out of 3 Years Active: 2025
Title: Innovations in Cancer Treatment by Jordi Surrallés Calonge
Introduction
Jordi Surrallés Calonge is a notable inventor based in Barcelona, Spain. He has made significant contributions to the field of cancer treatment through his innovative research and patents. His work focuses on the therapeutic use of afatinib, a drug that has shown promise in treating cancers associated with DNA damage repair defects.
Latest Patents
Jordi Surrallés Calonge holds a patent for the therapeutic use of afatinib in cancer. The patent outlines the use of afatinib or its pharmaceutically acceptable salts for the treatment and prevention of cancer in patients suffering from diseases caused by defects in DNA damage repair mechanisms. Remarkably, when afatinib was administered to Fanconi Anemia (FA) cells, it demonstrated a therapeutic anti-cancer effect without any toxic side effects on DNA. This discovery could pave the way for new treatment options for patients with specific genetic vulnerabilities.
Career Highlights
Throughout his career, Jordi has worked with prestigious institutions such as the Universitat Autònoma de Barcelona and the Consorcio Centro de Investigación Biomédica en Red. His research has contributed to a deeper understanding of cancer biology and potential therapeutic strategies.
Collaborations
Jordi has collaborated with esteemed colleagues, including Jordi Minguillón Pedreño and Helena Montanuy Escribano. These collaborations have enriched his research and expanded the impact of his work in the scientific community.
Conclusion
Jordi Surrallés Calonge's innovative approach to cancer treatment through his patent on afatinib highlights the importance of research in developing effective therapies. His contributions to the field are invaluable and continue to inspire advancements in cancer care.